Our leadership team

Edward L. Armstrong serves as Vice President, Quality Assurance at AVEO Oncology, an LG Chem company. In this capacity, he provides executive leadership for AVEO’s GxP quality and regulatory compliance functions, ensuring robust governance across clinical, commercial, and operational activities. Mr. Armstrong oversees quality management systems, inspection readiness, vendor oversight, risk management, and the development and implementation of policies and procedures that promote a culture of quality, compliance, and continuous improvement.

In addition to his quality leadership role, Mr. Armstrong serves as a strategic advisor on regulatory and compliance matters, supporting AVEO’s approved/commercial and pipeline products. His expertise spans GMP and GCP compliance, CMC and regulatory submission support, global regulatory expectations, quality systems implementation, and external partner oversight. Throughout his career, Mr. Armstrong has helped organizations strengthen compliance infrastructure, prepare for regulatory inspections, improve vendor and CDMO performance, and build resilient, high-performing quality teams.

Prior to AVEO, Mr. Armstrong served as Vice President and Head of Quality at Vedanta Biosciences, where he led strategic quality initiatives supporting clinical-stage microbiome therapeutics, directed GMP and GCP operations, strengthened inspection readiness, enhanced Qualified Person partnerships, restructured quality operations, and supported BLA readiness planning. Previously, he held senior quality leadership roles at Mustang Bio, Roche Molecular Diagnostics/IQuum, and Genzyme Corporation/Sanofi, where he built quality organizations, established GMP and GCP compliance programs, led quality system transformations, supported regulatory inspections, and implemented/integrated global quality systems.

Mr. Armstrong brings more than 30 years of experience in quality and compliance across pharmaceuticals, biotechnology, medical devices, microbiome therapeutics, and cell and gene therapy, with a proven track record of aligning fit-for-purpose quality systems with global regulatory expectations and enabling innovation in highly regulated environments.

Dr. Edgar Braendle serves as Chief Medical Officer of AVEO Oncology, an LG Chem company. Dr. Braendle is a life sciences executive bringing over 20 years of experience spanning from early drug discovery to the launch of small molecules, biologics, radiopharmaceuticals, gene and cell therapies, and medical device development.

Dr. Braendle most recently served as Chief Development Officer of Autolus Therapeutics Plc (Autolus), where he was responsible for all development functions and the conduct of a pivotal program in CD-19 directed genetically modified autologous T-cell immunotherapy for adult acute lymphoblastic leukemia, and the respective filing to the U.S. Food & Drug Administration and European Medicines Agency. Prior to his time at Autolus, Dr. Braendle held the role of Executive Vice President, Chief Medical Officer and Global Head of Development at Sumitomo Dainippon Pharma Oncology (Sumitomo), where he was responsible for a full range of development functions and progressed several early-stage, first in human programs and late-stage programs. Prior to his time at Sumitomo, Dr. Braendle served as President and CEO of ARUP Laboratories, a national clinical and anatomic reference laboratory. Dr. Braendle also spent over a decade at Novartis AG, where he served as Senior Vice President and Global Head of Companion Diagnostics and led the company’s precision medicine approach.

Dr. Braendle received his medical degree at RWTH Aachen University in Germany, followed by specialty training in medical oncology, urology and pharmacology. Dr. Braendle is also an associate professor at the University of Ulm, Germany.

David Crist brings more than twenty years of oncology sales experience in both launch-stage and late-stage companies, building commercial organizations and developing high performing sales force teams. During his career, Mr. Crist held oncology-focused sales roles at several leading pharmaceutical companies including MGI (Molecular Genetics, Inc), Eisai, Sanofi Genzyme, GlaxoSmithKline and ARIAD Pharmaceuticals, where he led their sales organization in the successful relaunch of  ICLUSIG^® (ponatinib), which contributed to the acquisition of ARIAD by Takeda Oncology in 2017. Following the acquisition, he continued at Takeda to successfully launch ALUNBRIG^® (brigatinib), which exceeded launch year and subsequent year forecasts nationally. Directly prior to joining AVEO Oncology, an LG Chem company, Mr. Crist served as general manager, hematology oncology U.S. franchise at argenx, a global immunology company, where he led commercial development for two of the company’s hematology and oncology compounds. Mr. Crist holds a B.S. from Florida State University.

Bob Fedak serves as the Vice President of Information Technology at AVEO Oncology, an LG Chem company. With an Information Technology career spanning over 20 years, Mr. Fedak brings his extensive experience in building and leading highly engaged information technology teams, while ensuring a company’s information technology contributes to a positive work experience for all employees. Prior to joining AVEO’s management team, Mr. Fedak served as the End User Experience/Service Management Lead at Akebia Therapeutics, Inc., where he was responsible for the strategic direction and overall productivity, efficiency and effectiveness of information technology services delivery and facility operations.

Mr. Fedak has also held several information technology positions in various healthcare organizations, including Shire Pharmaceuticals, LLC (now known as Takeda Pharmaceuticals Company Limited) and the American Red Cross. Mr. Fedak holds a Bachelor of Science in Information Technology from the University of Phoenix and a Master of Business Administration from Northeastern University.

Mike Ferraresso is President and Chief Executive Officer at AVEO Oncology, an LG Chem company. Before being appointed President and CEO, he served as Chief Commercial Officer for more than 5 years, leading the development and execution of AVEO’s commercial strategy and infrastructure and helping to transform the company into a successful commercial-stage organization. As a member of the Executive Leadership Team, he has also played a role in corporate strategy and business development, including strategic clinical collaborations and initiatives that supported AVEO’s growth and its acquisition by LG Chem, advancing the company’s position as LG Chem’s US oncology business.

Mr. Ferraresso brings more than 25 years of leadership experience in the pharmaceutical and biotechnology industries, including helping 5 biotechnology companies advance into commercial organizations through successful first product launches. Prior to joining AVEO, he held commercial leadership positions at Verastem, Infinity Pharmaceuticals, AMAG Pharmaceuticals, Critical Therapeutics, Praecis Pharmaceuticals, Ascent Pediatrics, and Muro Pharmaceuticals. His expertise spans corporate strategy, business development, partnerships, product development, and commercialization.

Mr. Ferraresso earned a Bachelor of Arts in Economics from Assumption College.

Barbara Fielman has more than 25 years of experience in the pharmaceutical industry, and rejoins AVEO Oncology, an LG Chem company, as Senior Vice President of Clinical Operations and Site Engagement.

Ms. Fielman most recent experiences include her leading the clinical operations teams at Hookipa Pharma, Inc. and Sumitomo Pharma America (formerly Sumitomo Pharma Oncology) (“Sumitomo”) to work on several biologics programs. Prior to Ms. Fielman’s time at Sumitomo, she held several senior-level positions within clinical operations at Dicerna Pharmaceuticals (now Novo Nordisk A/S) and AVEO Oncology.  Before her time at AVEO Oncology, Ms. Fielman worked at Idenix Pharmaceuticals, Inc. (a wholly owned subsidiary of Merck Sharp & Dohme) and GlaxoSmithKline plc focusing on HIV, Hepatitis B and C for more than 10 years.  During her career in the pharmaceutical industry, Ms. Fielman has participated in 3 successful NDA/BLAs.  Prior to entering the pharmaceutical industry, Ms. Fielman was an Intensive Care Nurse and Pediatric Nurse Practitioner at Boston Children’s Hospital and Dallas Children’s Hospital.

Ms. Fielman received her Bachelor of Science degree in Nursing from Boston University and her Master of Science degree in Nursing from Northeastern University.

Danielle Holland serves as Senior Vice President, General Counsel and Corporate Secretary of AVEO Oncology, an LG Chem company. Prior to joining AVEO, Ms. Holland served as an Associate at Skadden, Arps, Slate, Meagher & Flom LLP where she advised public and private clients in a variety of industries in corporate and securities law matters, mergers and acquisitions, governance, corporate finance and other matters. Prior to her legal career, Ms. Holland taught elementary education in New York City through Teach For America. Ms. Holland received a B.A. in International Studies from Boston College and a J.D. from Boston University School of Law.

Dr. Andy Hwang brings over 15 years of experience in clinical operations and drug development, with a focus on early-phase oncology and immunology programs. He currently serves as Vice President of Clinical Operations at AVEO Oncology, an LG Chem company.

Dr. Hwang most recently served as Vice President of Clinical Operations at Sail Biomedicines, where he led the clinical operational buildout and trial planning for RNA-based therapies in autoimmune disease. Prior to that, he was Vice President and Head of Clinical Operations at Hookipa Pharma, where he oversaw global Phase I/II trials in oncology and infectious diseases. Earlier in his career, Dr. Hwang held senior clinical operations and trial management roles at Bayer HealthCare and Novartis, supporting first-in-human and translational studies in various solid tumors and hematologic malignancies.

Over the course of his career, Dr. Hwang has led more than 10 global Phase I/II trials across North America, Europe, and Asia, spanning small molecules, monoclonal antibodies, ADCs, and viral vectors. He has built and led high-performing clinical teams and contributed to corporate strategy, operational excellence, and regulatory readiness.

Dr. Hwang earned his Doctor of Pharmacy degree from the University of Southern California and a BS in Psychology-Biology from the University of California, Los Angeles. He completed a postdoctoral fellowship in early development and oncology clinical research at Rutgers University.

Mr. Jeong serves as as Chief Financial Officer of AVEO Oncology, an LG Chem company. Mr. Jeong joins AVEO from its parent company, LG Chem, Ltd. (“LG Chem”), where he has served as a financial and accounting officer since 1999. During his time at LG Chem, Mr. Jeong has served as the financial director and controller for several entities where LG Chem invested in joint ventures and/or subsidiaries, the majority of them in Thailand. He has provided strategic financial counsel on the new entities’ successful stabilization, spearheaded the implementation of financial controls and systems, and overseen the expansion of the Finance/Accounting departments.

Mr. Jeong received his B.S. in Business Administration from Kyunghee University in South Korea.

Dr. Bo Jin serves as Vice President of Biostatistics and Data Management at AVEO Oncology, an LG Chem company, bringing over 20 years of industry experience in biostatistics, data management, programming, and data sciences.

Dr. Jin most recently served as Vice President of Biostatistics and Programming at SinoCellTech Group Limited (SinoCell), where he was responsible for the Biostatistics and Statistical Programming functions and company data science strategy. Prior to his time at SinoCell, Dr. Jin held the role of Vice President of Data Science at Sumitomo Pharma Oncology (SMPO), where he was responsible for Biostatistics, Data Management, Statistical Programming, Data Standard, and Data Science operational excellence and innovations.  Before his time at SMPO, Dr. Jin spent more than a decade with Merck & Co, Inc., and Pfizer Inc., where he held various leadership roles and was the statistician for the successful launch of several products in both general medicine and oncology.

Dr. Jin received a PhD in Statistics from Virginia Tech and his MBA from the University of Massachusetts Amherst.

Dr. Claudia Lebedinsky serves as Senior Vice President, Clinical Development of AVEO Oncology, an LG Chem company, bringing more than 20 years of experience in oncology and clinical development to the organization.

Dr. Lebedinsky most recently served as Vice President, Head of Clinical Development at Sumitomo Pharma Oncology (Sumitomo), where she led the clinical development of novel small molecules and peptides vaccines. Prior to her time at Sumitomo, Dr. Lebedinsky held a variety of clinical development roles for early and late phase drug development at multiple companies, including PharmaMar, Sanofi Oncology, Novartis AG and Baxalta (a subsidiary of Takeda Pharmaceutical Company, a Dyax Corporation). During this time, Dr. Lebedinsky led the development of several marketed oncology drugs, including YONDELIS^®, INREBIC^®, and ASPARLAS^®. Dr. Lebedinsky conducted her residence in medical oncology at Instituto de Oncologia Roffo, Argentina. She is a board-certified medical oncologist by Argentina Ministry of Health and Spain Ministry of Health.

Dr. Stan Lechpammer serves as Vice President, Medical Affairs at AVEO Oncology, an LG Chem company. Dr. Lechpammer is a physician-scientist and medical affairs executive, bringing more than 20 years of experience in oncology across the biotechnology and pharmaceutical industry.

Dr. Lechpammer most recently served as Vice President, Head of Medical Affairs and Innovative Medicines at Fosun Pharma USA, where he led medical and clinical affairs activities and supported the development and launch strategy for serplulimab (anti-PD-1 mAb) in extensive-stage small-cell lung cancer. Prior to his time at Fosun, Dr. Lechpammer held positions of increasing responsibility at organizations including ImmunityBio, GSK, Pfizer, Medivation, Jazz Pharmaceuticals, EMD Serono, Genzyme, Onyx Pharmaceuticals, and Amgen. He played key roles in the development, launch, and lifecycle management of numerous oncology therapies, including Anktiva^®, Zejula^®, Xtandi^®, Talzenna^®, Defitelio^®, Campath^®, Nexavar^®, and Vectibix®.

Dr. Lechpammer obtained MD and PhD degrees from the University of Zagreb School of Medicine in Croatia, EU and completed a post-doctoral fellowship in Radiation Oncology and clinical research fellowship in Nuclear Medicine at Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School in Boston, MA.

Cathy serves as Vice President, Human Resources at AVEO Oncology, an LG Chem company, where she leads the company’s people strategy to support its mission and growth. She brings over 20 years of experience across both small biotech and large pharmaceutical organizations, building thoughtful, scalable HR programs that strengthen teams, develop leaders, and enhance the overall employee experience.

She is a certified Leadership Coach, bringing a practical, people-centered approach to fostering high-performing teams. She is energized by creating environments that empower people to do their best work and deliver meaningful impact for patients.

Cathy holds a bachelor’s degree in human resources from American University and a master’s degree from Boston College.

Jason Noto brings over 25 years of broad commercial leadership experience to his role as Senior Vice President of Market Access & Alliance Management at AVEO Oncology, an LG Chem company. Prior to joining AVEO, Jason served as Vice President at 1798 Consultants, a strategic market access consultancy specializing in integrated channel strategy, patient support services (HUB), payer contract development and assessment, financial impact analysis, and related access functions. Earlier, Mr. Noto served as Senior Director of Market Access Strategy and Payer Marketing at Amag Pharmaceuticals, leading payer marketing efforts across all business units totaling over >$600M in revenue in 2019.

Prior to his tenure at Amag Pharmaceuticals, Mr. Noto held various sales and marketing leadership roles of increasing responsibility at Sunovion Pharmaceuticals, Alkermes, and Bristol Myers Squibb. During his career, Mr. Noto has had responsibility for the US commercial launch of various specialty products in oncology, immunology, CNS, and ultra-orphan disease states. Mr. Noto received a BS in Business Administration from Le Moyne College and an MBA from Boston College.

Greg Oehrtman brings over 20 years of Drug Development experience to his role returning to AVEO Oncology, an LG Chem company, after 8 years. Dr. Oehrtman has held roles of increasing seniority in Drug Development and Manufacturing at Quintiles/Catalent, Amylin, Stealth Biotherapeutics, and Dicerna. He has led both drug substance and product development and manufacturing from early pre-clinical to commercial validations, supporting development of Fast Acting Advil, Advil PM, Bydureon, FOTIVDA, Elamipretide, and Nedosiran. While in these roles, he has managed product development of small molecules, peptides, and antibodies as oral and sterile injectable along with combination device development. Dr. Oehrtman received his Ph.D in Chemical Engineering from Massachusetts Institute of Technology.

Michael Palliola currently serves as Vice President, Thought Leader Engagement & Strategic Partnerships at AVEO Oncology, an LG Chem Company. He brings over 20 years of commercial experience in the biotech/pharmaceutical space, primarily in launch stage organizations.

During his career, Michael has held oncology roles in sales, sales training, US/Global marketing, brand management, and KOL strategy at organizations including GlaxoSmithKline, Sanofi, Dendreon, Tesaro, which was later acquired by GSK, and EMD Serono.

Prior to his current role, Michael led the design and build out of the Opinion Leader Liaison function at EMD Serono, which was responsible for managing thought leader relationships for their Genitourinary and Lung portfolio.

Michael holds a BA in Neuroscience & Spanish from Bowdoin College and an MBA in Healthcare Management from the Heller School of Social Policy & Management at Brandeis University.

Kevin Peacock serves as Chief Commercial Officer at AVEO Oncology, an LG Chem company. Prior to his appointment as Chief Commercial Officer, he served as Senior Vice President of Marketing and Business Analytics, where he led the overall commercial strategy for FOTIVDA^®, overseeing brand strategy, business analytics, market insights, and new product planning across the company’s portfolio.

Mr. Peacock joined AVEO Oncology in 2019, bringing 20 years of pharmaceutical industry experience across commercial strategy, marketing, business analytics, and lifecycle management. Throughout his tenure at AVEO, he has played a key leadership role in advancing the company’s commercial organization and driving the successful commercialization and continued growth of FOTIVDA^®.

Prior to joining the company, Mr. Peacock served as the Vice President of New Product Planning and Business Development at Lycera, where he led the early commercialization strategy for the company’s novel immune-oncology pipeline, and in 2015 helped complete an exclusive strategic collaboration and licensing agreement with Celgene that resulted in $100M in non-dilutive financing. He previously served as Vice President of Global Marketing and Business Analytics at Dendreon, where he led the launch of Provenge^® in select European markets and oversaw the US Business Analytics team. Earlier in his career, he served as Senior Director and Product Champion for Krystexxa^® at Savient Pharmaceuticals, Senior Director of New Product Planning at Allos Therapeutics, and held multiple commercial roles supporting the ERBITUX^® brand at ImClone Systems.

Mr. Peacock earned a Bachelor of Business Administration in Finance and Risk Management from Temple University.

Eric Solowey serves as Vice President, Legal, at AVEO Oncology, an LG Chem company. Mr. Solowey is an experienced life sciences attorney and advisor. Immediately prior to joining AVEO, Mr. Solowey served as Vice President and Assistant General Counsel at Parexel International Corporation, a contract research organization serving biopharmaceutical companies worldwide. Mr. Solowey earned a BA from Harvard College and a JD from George Washington University Law School.

Dr. Adebunmi (Bunmi) Urakpo serves as Vice President of Pharmacovigilance for AVEO Oncology, an LG Chem Company, bringing over 20 years of experience in drug safety and pharmacovigilance, clinical research, and public health.

Dr. Urakpo most recently served as a Pharmacovigilance and Drug Safety Consultant at NADDBio LLC (“NADDBio”), a clinical-stage R&D consultancy firm. Prior to joining NADDBio, Dr. Urakpo worked at PrimeVigilance Ltd. (“PrimeVigilance”), where she held positions of increasing responsibilities to eventually become the Senior Medical Director and the Head of Medical Operations. She also served as Interim Head of the Benefit Risk Department while at PrimeVigilance. Dr. Urakpo was an EU/UK Qualified Person for Pharmacovigilance (QPPV) for over eight years.

Dr. Urakpo holds a medical degree from the University of Ibadan (Nigeria), a master’s in public health from the University of Liverpool, a postgraduate diploma in pharmacovigilance from the University of Hertfordshire and an MBA certification from the London School of Economics.

Anisha Wharton is the Vice President of Regulatory Affairs at AVEO Oncology, an LG Chem company, where she brings over 21 years of strategic regulatory leadership spanning global drug development, product registration, and lifecycle management across both biologics and pharmaceutical portfolios. As a strategic leader, she is responsible for guiding AVEO through complex regulatory frameworks to ensure product safety, efficacy, and market access.

Since joining AVEO in 2021, Ms. Wharton has been instrumental in shaping the company’s regulatory strategy, guiding cross-functional teams to advance oncology assets through complex regulatory landscapes.

Previously, Ms. Wharton served as Director, Global Regulatory Affairs – Oncology at Merck & Co., Inc., where she led global regulatory strategy for both early- and late-stage development programs targeting advanced metastatic tumors, women’s cancers, melanoma, and multiple myeloma. Among her key accomplishments, she oversaw the successful global approval of a new Q6W dosing regimen for KEYTRUDA^® across all approved adult indications, securing market access in over 35 countries.

Earlier in her career, Ms. Wharton held increasingly senior regulatory leadership roles at Nektar Therapeutics, InterMune, Inc. (acquired by Roche), InSite Vision, Inc. (acquired by Sun Pharma), and Genentech. She played a pivotal role in the US and EU approvals of ESBRIET^® (InterMune, Inc.) and AZASITE^® (InSite Vision, Inc.), and led initiatives to strengthen global regulatory intelligence and operational excellence.

Ms. Wharton holds a BS from Clark Atlanta University and an MBA from the University of San Francisco School of Management.